Webinars

AET Europe 2020: Advancing Therapeutic Antibody discovery using RenMab/RenLite/RenMab KO immunoglobulin humanized mouse platforms

To meet the expanding needs of the therapeutic antibody market, Biocytogen established first and second generation of immunoglobulin humanized mouse platforms: RenMab, RenMab KO and RenLite.

IO Summit Boston: Improve Translation of Humanized Animal Models for Immunotherapy

Learn about the new developments in humanized animal models to get ideas on how models can be applied to solve specific translational challenges.

Accelerating Therapeutic Antibody Discovery with Three Distinct Humanized Mouse Models

With a robust immune response, RenMab™ Mouse produces fully-human, functional antibodies of high antigen specificity and diverse epitopes.

The use of genetically modified mouse models and in vitro cell culture models

Here we introduce a new screening strategy for antibody drugs, by which not only can people minimize the risk of potential “red flags”, but also reduce the time and cost.

Humanized Animal Models for Immunotherapy

Development and application of humanized animal models, which mimic human immunity and therapeutic targets, may provide promising solution to the challenges of preclinical translation

In Vivo vs. In Vitro Therapeutic Antibody Discovery

in vivo antibody discovery using transgenic/humanized mice is of rising importance for the antibody community as it offers a multitude of benefits over in vitro methods

AET Europe 2020: Advancing Therapeutic Antibody discovery using RenMab/RenLite/RenMab KO immunoglobulin humanized mouse platforms

IO Summit Boston: Improve Translation of Humanized Animal Models for Immunotherapy

Accelerating Therapeutic Antibody Discovery with Three Distinct Humanized Mouse Models

The use of genetically modified mouse models and in vitro cell culture models

Humanized Animal Models for Immunotherapy

In Vivo vs. In Vitro Therapeutic Antibody Discovery

Webinars Category

Empowering Health Sciences News